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Background and Objectives. Influenza virosomes represent an innovative human-compatible antigen delivery system that
has already proven its suitability for subunit vaccine design. The aim of the study was to proof the concept that virosomes can
also be used to elicit high titers of antibodies against synthetic peptides. The specific objective was to demonstrate the safety
and immunogenicity of two virosome-formulated P. falciparum protein derived synthetic peptide antigens given in two
different doses alone or in combination. Methodology/Principal Findings. The design was a single blind, randomized,
placebo controlled, dose-escalating study involving 46 healthy Caucasian volunteers aged 18–45 years. Five groups of 8
subjects received virosomal formulations containing 10 mg or 50 mg of AMA 49-CPE, an apical membrane antigen-1 (AMA-1)
derived synthetic phospatidylethanolamine (PE)-peptide conjugate or 10 ug or 50 ug of UK39, a circumsporozoite protein
(CSP) derived synthetic PE-peptide conjugate or 50 ug of both antigens each. A control group of 6 subjects received
unmodified virosomes. Virosomal formulations of the antigens (designated PEV301 and PEV302 for the AMA-1 and the CSP
virosomal vaccine, respectively) or unmodified virosomes were injected i. m. on days 0, 60 and 180. In terms of safety, no
serious or severe adverse events (AEs) related to the vaccine were observed. 11/46 study participants reported 16 vaccine
related local AEs. Of these 16 events, all being pain, 4 occurred after the 1st, 7 after the 2nd and 5 after the 3rd vaccination. 6
systemic AEs probably related to the study vaccine were reported after the 1st injection, 10 after the 2nd and 6 after the 3rd.
Generally, no difference in the distribution of the systemic AEs between either the doses applied (10 respectively 50 mg) or the
synthetic antigen vaccines (PEV301 and PEV302) used for immunization was found. In terms of immunogenicity, both PEV301
and PEV302 elicited already after two injections a synthetic peptide-specific antibody response in all volunteers immunized
with the appropriate dose. In the case of PEV301 the 50 mg antigen dose was associated with a higher mean antibody titer and
seroconversion rate than the 10 mg dose. In contrast, for PEV302 mean titer and seroconversion rate were higher with the
lower dose. Combined delivery of PEV301 and PEV302 did not interfere with the development of an antibody response to
either of the two antigens. No relevant antibody responses against the two malaria antigens were observed in the control
group receiving unmodified virosomes. Conclusions. The present study demonstrates that three immunizations with the
virosomal malaria vaccine components PEV301 or/and PEV302 (containing 10 mg or 50 mg of antigen) are safe and well
tolerated. At appropriate antigen doses seroconversion rates of 100% were achieved. Two injections may be sufficient for
eliciting an appropriate immune response, at least in individuals with pre-existing anti-malarial immunity. These results justify
further development of a final multi-stage virosomal vaccine formulation incorporating additional malaria antigens. Trial
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INTRODUCTION
Apart from plans to develop a radiation-attenuated sporozoite
vaccine [1], vaccine development against Plasmodium falciparum
malaria is focusing largely on subunit vaccine technologies.[2] It is
thought that an effective malaria subunit vaccine will have to
incorporate antigens against several development stages of the
parasite. A combination of immune responses against sporozoites,
infected liver cells, merozoites and infected red blood cells may be
required to achieve substantial protective activity .[2] Attempts to
produce such a multi-stage subunit vaccine against malaria have so
far met with limited success, indicating that new strategies both for
the targeting of the immune response to suitable antigenic
determinants of the parasite and for the safe and appropriate
delivery of antigens are required. We are addressing these
problems by developing synthetic peptide structures that elicit
antibodies against the native conformation of the malaria antigens
[3–5], and by displaying them as PE-peptide conjugates on the
surface of immunopotentiating reconstituted influenza virosomes
(IRIV) as carrier and adjuvant system. [3;6]
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IRIVs are spherical, unilamellar vesicles, prepared by detergent
removal from a mixture of natural and synthetic phospholipids
and influenza surface glycoproteins. The haemagglutinin of the
influenza virus is a fusion-inducing membrane glycoprotein, which
facilitates antigen delivery to immunocompetent cells. IRIVs
represent an universal antigen-delivery system for multi-compo-
nent subunit vaccines, since antigens can be either attached to
their surface to elicit CD4 T cell and antibody responses or
encapsulated in their lumen to elicit CD8 T cell responses. They
have an excellent safety profile and are already registered for
human use, as two virosomal vaccines, the influenza vaccine
Inflexal VH and the hepatitis A vaccine EpaxalH are commercial-
ized.[7] More than 20 million doses of Epaxal or Inflexal V have
been applied so far. These virosomal vaccine formulations are able
to induce specific immunity without inducing a non-specific
inflammatory response and have therfore an excellent local
tolerability not only in adults but also in children [8–10].
We have previously shown that synthetic peptide vaccine
antigens which bypass many of the problems associated with the
production of stable recombinant protein-based formulations can
be developed by iterative cycles of compound design, synthesis and
immunological profiling.[3–6] Sequential rounds of optimization
may lead to candidate antigens which elicit primarily antibodies
that contribute to immune protection when displayed as
phosphatidylethanolamine (PE)-peptide conjugates on the surface
of IRIVs. CSP of P. falciparum is a leading sporozoite candidate
antigen for inclusion in a malaria subunit vaccine. In a stepwise
medicinal chemistry lead optimization process [3,11–13], we have
developed the conformationally constrained synthetic compound
UK-39, which has best possible structural and antigenic similarity
to the immunodominant NANP-repeat region of native CSP.
PEV302, the virosomal formulation of UK-39, elicits high titers of
sporozoite cross-reactive antibodies in mice and rabbits and these
antibodies inhibit invasion of liver cells by P. falciparum sporozoites
(Pluschke et al, personal communication). AMA-1 of P. falciparum is
a leading merozoite candidate antigen. Its ectodomain can be
divided into three subdomains each with disulfide bond-stabilized
structures. Since the majority of antibodies raised against the
ectodomain appear to recognize epitopes in domain I that are
strain-specific, we have develop a synthetic antigen based on the
more conserved loop-I of domain III, which interacts with the
erythrocyte membrane protein Kx.[14] PEV301, the virosomal
formulation of the optimized loop-I derived cyclized peptide
antigen AMA49-C1, elicits high titers of blood stage parasite cross-
reactive antibodies in mice and rabbits and these antibodies
recognize primarily discontinuous epitopes comprising conserved
sequence stretches of AMA-1.[4] Monoclonal antibodies generat-
ed from PEV301 immunized mice have shown P. falciparum blood
stage growth inhibitory activity in vitro.[4]
Here we describe the first clinical profiling of virosomal
formulations of two optimized synthetic antigens, the circumspor-
ozoite protein (CSP) repeat region derived PE-peptide conjugate
UK-39 and the apical membrane antigen-1 (AMA-1) derived PE-
peptide conjugate AMA49-C1.[4] The specific objectives of the
Phase l trial were to demonstrate the safety, tolerability and
immunogenicity of PEV301 and PEV302 incorporating two
different amounts of PE-peptide conjugate (10 mg or 50 mg per
dose) given alone or in combination (50 mg of each conjugate).
METHODS
This prospective phase I, single blind, randomized, placebo
controlled, dose-escalating study was conducted in 46 healthy
adult volunteers at the Clinical Research Center, University
Hospital, Basel, Switzerland.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Healthy volunteers of both sexes, aged between 18 and 45 years,
with a BMI .18.5 and ,30 were included if they gave written
informed consent. Volunteers were excluded if they lived in the past
in a malaria endemic area, had visited such an area in the last
12 months, had a history of clinical malaria, had used any
investigational or non-registered drug or vaccine within 30 days
preceding the first dose of study vaccine, had acute or chronic,
clinically significant pulmonary, cardiovascular, hepatic or renal
functional abnormality, as determined by physical examination or
laboratory screening tests, had diabetes, had history of chronic
alcohol consumption and/or intravenous drug abuse, had any
confirmed or suspected acquired immunosuppressive or immuno-
deficient condition, including human immunodeficiency virus (HIV)
infection, or history of congenital or hereditary immunodeficiency,
had a history of allergic disease or reactions likely to be exacerbated
by any component of the vaccine, had acute disease at the time of
enrolment, were under immunosuppressive drugs within six months
prior to the first vaccine dose, were under chronic drug therapy, were
pregnant or planning to become pregnant for female volunteers.
Vaccine
Two virosome-formulated P. falciparum malaria vaccines PEV301
(incorporating the AMA-1 derived PE-peptide conjugate AMA49-
C1) and PEV302 (incorporating the CSP derived PE-peptide
conjugate UK-39) were produced according to the rules of GMP.
Tests for sterility, pyrogenicity, immunogenicity in animals,
stability and chemical composition were performed on the vaccine
lots used in this trial. Each dose was composed of 10 or 50 mg
AMA49-C1 or UK-39, 10 mg Influenza haemaglutinine, 100 mg
phospholipids and PBS ad 0.500 ml.
During the course of the study, stability tests were performed. We
identified an unusual curve profile of PEV301 analyzed by HPLC.
Validated or standardized potency tests were not available at that
stage, but immunization studies in mice have shown that the clinical
lot induced the expected humoral immune response. Nevertheless,
the potential stability problem may have slightly impacted on the
immunogenicity of this component, but has been solved since then,
thanks to lyophilization of the vaccine candidate.
Intervention
Five groups of 8 participants received virosomal formulations
containing 10 ug or 50 ug of AMA49-C1, an AMA-1 derived
synthetic phosphatidylethanolamine (PE)-peptide conjugate, or
10 ug or 50 ug of UK-39, a CSP derived synthetic PE-peptide
conjugate, or 50 ug of both antigens each. Vaccine formulations
contained different amounts of PE-peptide conjugate, but
throughout the same amounts of IRIV per dose. The combination
of PEV301 and PEV302 contained the double amount of
influenza protein. A control group of 6 participants received
unmodified virosomes. Virosomal formulations of the antigens or
unmodified virosomes. The trial vaccines and comparator were
administered i.m. in the left arm on day 0, in the right one on day
60 (65 day), and the left one on day 180 (65 days).
Objectives
The aim of the study was to prove the concept that virosomes can
be used to elicit high titers of antibodies against synthetic peptides
derived from malaria antigens. The objectives were to demon-
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strate the safety and immunogenicity of two virosome-formulated
P. falciparum protein derived synthetic peptide antigens given in two
different doses alone or in combination. The trial was designed to
investigate whether there was a dose effect of the antigens, and
whether the combination of the two antigens led to beneficial,
neutral or deleterious effects on safety and immunogenicity.
Outcomes
Safety Occurrence of local and systemic adverse events assessed
by the physician in charge for 30 minutes, and on days 2 (or 3) and 7
(62 days) after each vaccination, and by the subject him/herself on
a diary card for 4 days. Intensity of local adverse events was graded
as follows: for pain, 0 = absent, 1 = painful on touch, 2 = painful
when moved, 3 = spontaneously painful; for redness and swelling,
0 =#5, 1 =.5-#20 mm, 2 =.20-#50 mm, 3 =.50 mm. For all
other adverse events, grading and reporting was done according to
Common Terminology Criteria for Adverse Events v3.0 (CTCAE).
Haematological and biochemical analysis was carried out at
screening visit (baseline), 7 (62) and 21 (65) days after each
vaccination.
Immunogenicity Antibody titer measured by ELISA against
AMA49-C1 and UK-39 during the screening visit and on days 21
(65 days), 60 (63) (2nd vaccination), 81 (+5), 180 (+3) (3rd
vaccination) and 201 (+5), as well as one year after the third
vaccination (the latter for groups PEV302 10 mg, PEV301 50 mg
(n = 8; group C) and PEV301 50 mg+PEV302 50 mg.
Sample Size The sample size of this pilot study was determined
by the requirement to prove the principle that the virosome-
formulated synthetic peptides were safe and immunogenic. An
overall sample size of 40 is generally considered appropriate in first
Phase I trials to estimate the incidence rate of frequent AEs with an
acceptable accuracy, allowing for dropouts. The study was not
powered to ensure that differences in safety or immunogenicity
between regimens would be statistically significant.
Randomization–sequence generation
Eligible study participants were randomly allocated in six groups:
PEV301 10 mg (n = 8; group A), PEV302 10 mg (n = 8; group B),
PEV301 50 mg (n = 8; group C), PEV302 50 mg (n = 8; group D),
PEV301 50 mg+PEV302 50 mg (n = 8; group E) or unmodified
virosomes (IRIVs) serving as controls (n = 6; group F). Sequence
generation for the randomization was computer performed (SAS
software). The first 18 volunteers were stratified into males and
females and then randomized by two blocks of 9 (1 block = fe-
males, 1 block = males) in 3 groups: PEV301 10 mg (n = 8),
PEV302 10 mg (n = 8), and IRIVs alone (control; n = 2). Five
weeks later, another 18 volunteers followed the same procedure:
PEV301 50 mg (n = 8), PEV302 50 mg (n = 8), and IRIVs (n = 2).
Five weeks after the 2nd vaccination of previous groups, 10
volunteers were randomized in blocks of 5 to either the
combination of PEV301 & PEV302 50 mg (n = 8) or IRIVs (n = 2).
Randomization–Allocation concealment
Allocation concealment was done using sealed envelopes with
numbers (1 to 46) corresponding to the sequence of assignment to
the study. All procedures for screening and group allocation of one
subject were completed before the next subject was seen.
Randomization–Implementation
The randomization was done by PV, statistician at the Swiss
Tropical Institute, who did not have any contact with the
clinicians or the participants. The physician in charge of the
screening and inclusion of the participants opened the envelopes
sequentially, using one block for each sex.
Blinding
The study was single blind (participant unaware of product applied).
Laboratory methods
ELISA polysorp microtiter plates (Nunc, Dr. Grogg, Stetten-
Deiswill, Switzerland) were coated at 4uC overnight with 10 mg/
ml AMA49-C1 (for PEV301) or UK-39 (for PEV302) in PBS, pH
7.2. Wells were then blocked with 5% milk powder in PBS for 2 h
at 37uC followed by three washings with PBS containing 0.05%
Tween-20. Plates were then incubated with two-fold serial
dilutions of human serum starting with 1:50 in PBS containing
0.05% Tween-20 and 0.5% milk powder for 2 h at 37uC. After
washing, the plates were incubated with horseradish-peroxidase-
conjugated goat anti-human IgG antibodies (KPL, Socochim,
Lausanne, Switzerland) (1:2000 in PBS containing 0.05% Tween-
20) for 1 h at 37uC and then washed. Citrat-buffer containing
4 mg/ml 1,2-diaminobezene substrate (OPD; Fluka, Sigma,
Buchs, Switzerland) and 0.01% H2O2 was added and incubated
at room temperature. After 10 minutes the reaction was stopped by
addition of sulphuric acid (Merck, Darmstadt, Germany) to reach
a final concentration of 0.5M. The optical density (OD) of the
reaction product was recorded at 492 nm using a microplate reader
(SpectraMax plus, Bucher Biotech, Basel, Switzerland). Titration
curves were registered using Softmax PRO software. Endpoint titers
were calculated by comparing the ELISA OD of the test serum with
the ELISA OD of a negative serum pool. Endpoint titer is last serum
dilution where the ODtest sera$26ODnegativ serum.
Statistical Methods
The safety analysis population included all participants who received
at least one injection, independently from protocol deviations.
Data collected from drop-outs were used for the statistical analysis
until the date of discontinuation. Safety of the injected study
materials was determined as the incidence of adverse events and
the occurrence of significant clinical, haematological and bio-
chemical abnormalities during the procedure and at the intervals
indicated in the schedule of assessments. The safety analysis
population listings were made of the safety data collected at each
time point.
The Per Protocol (PP) immunogenicity analysis population included all
participants, who received the three doses of the allocated product
in the allowed intervals and timely attended all the scheduled
blood sampling visits. The Intention-to-treat (ITT) immunogenicity
analysis population included all participants and all time points,
independently from protocol deviations (which mainly consisted in
a 1–2 day deviation from the allowed time interval). Data collected
from drop-outs were included for ITT analysis until the date of
discontinuation.
The criteria for the evaluation of immunogenicity of PEV301
and PEV302 were the results of antibody titers by Elisa against
AMA49-C1 and UK-39. ELISA responders were defined as
participants with a minimum titer $1:500 and a .2 fold increase
after immunization.
The geometric means and 95% confidence intervals of the
antibody titers determined by ELISA (total IgG) for PEV 301 and
PEV 302 in the four different groups were calculated separately for
each time point and study group. The statistical significance of the
vaccine component effects was tested using a Wilcoxon test to
compare the median of the antibody titers between group A
(PEV301 10 mg) and 3 (PEV301 50 mg), group A (PEV301 10 mg)
IRIV Peptide Malaria Vaccine
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and 5 (PEV301&302 50 mg) and group C (PEV301 50 mg) and 5
(PEV301&302 50 mg) at each study week assessment. Same was
done for the respective groups of PEV302. The Fishers exact test
was applied to compare the proportion of respondents between the
groups above and at each time point with the exception weeks 9/
10 and 26/27 where the titre could not be determined.
Indices of antibody response were expressed as the ratio of the
antibody concentration obtained by Elisa at the 4, 12/14 and 29/
30 weeks with reference the baseline measurement point. The
geometric mean and 95% confidence limits were calculated and
the Wilcoxon test was used to compare between groups and
between the follow-up times at the 4, 12/14 and 29/30 week and
the baseline. P,0.05 was considered as significant.
Ethics and regulatory bodies
The protocol was approved by the Ethikkommission beider Basel
(EKBB) and the study carried out in full compliance with the
international ethical guidelines for biomedical research involving
human participants and the guidelines of Good Clinical Practice.
Clearance for conducting the study was also given by the Swiss
Agency for Therapeutic Products (Swissmedic).
Plans were made for a Data and Safety Monitoring Board
(DSMB) to be established if one of the following situations would
have occurred: -one or more participants experienced a serious
adverse reaction assessed as related to the vaccine by the
investigator, -one or more participants experienced anaphylaxis,
-two or more participants in a single dose and antigen cohort
experienced a severe adverse event not explained by a diagnosis
unrelated to vaccination.
Participants were financially compensated for the time lost and
expenses incurred by the study requirements (transport etc.).
Data Quality Management
The study was monitored by the Pharmaceutical Medicine Unit
(PMU) of the Swiss Tropical Institute (STI) according to
a monitoring plan.
RESULTS
Recruitment
The study was conducted from November 2003 to October 2005.
46 Caucasian participants (half female, see Methods) were enrolled
as planned.
Participant flow
All 46 participants received the 1st injection, 44 the 2nd and 43 the
3rd. Three participants discontinued participation in the trial, all of
them due to a systemic AE (one of them possibly related to the
study vaccine) (see below and study flowchart on figure 1).
Baseline data
Demographic and other baseline characteristics of the population
enrolled in the study are listed in Table 1.
Numbers analyzed
All 46 participants were included in the safety analysis population
after 1st injection, 44/46 after 2nd injection and 43/46 after 3rd
injection. 37/46 participants constituted the per-protocol immu-
nogenicity analysis population (see study flowchart on figure 1 for
details). Protocol deviations leading to exclusion from the latter
population were 5 times follow-up visit dates that slightly differed
from the planned schedule and once the 2nd vaccination that was
slightly delayed (1 subject in PEV301 50 mg , 2 in PEV302 10 mg ,
1 in PEV301 & 302 50 mg and 2 in IRIV).
Outcomes and estimation
Safety No serious or severe AE occurred after the 1st, 2nd or 3rd
vaccination. Exclusively pain was reported as local AE, i.e. no
subject experienced at any time redness and/or swelling at the
injection site. In total, 16 local AEs were reported by 11 study
participants (3 from PEV301 10 mg , 2 from PEV301 50 mg , 2
from PEV302 50 mg , 2 from PEV301 & 302 50 mg and 2 from
IRIV) during the period of the trial. Of these 16 events, 4 occurred
after the 1st, 7 after the 2nd and 5 after the 3rd vaccination. No
volunteer from PEV302 10 mg suffered from local AEs. Ten events
(62.5%) were of mild and 6 (37.5%) of moderate intensity. All
listed local vaccine related AEs completely resolved without
sequelae within maximal 3 days after injection and no intervention
was required to treat any of the local AEs.
In total 69 systemic AEs (6 possibly related and 63 either
unrelated, or unlikely related to the study vaccine) were reported
by 31 participants after the 1st vaccination, 44 systemic AEs (10
possibly related and 34 unrelated/unlikely related) by 22
participants after the 2nd immunization, and 18 systemic AEs (6
possibly related and 12 unrelated/unlikely related) by 13
participants after the 3rd injection. One serious, vaccine unrelated,
adverse event was reported in the PEV302 10 mg group after the
1st immunization (hospitalization for tooth abscess). This subject
and two others voluntarily discontinued participation in the trial,
the first two prior to the 2nd and the last prior to the 3rd
vaccination. Only one was graded as possibly related by the
investigator [described as dishydrosis (dryness of the skin), which
first appeared with mild intensity on the right palm and developed
thereafter to moderate intensity on both hands and feet].
The type and distribution of vaccine related systemic AEs is
shown in Table 2. Generally, no difference in the distribution of
the systemic AEs between either the doses applied (10 respectively
50 mg) or the synthetic antigens (PEV301 and PEV302) was found.
No possibly related systemic AE was experienced by volunteers
from the IRIV group and less flu-like symptoms were reported in
the IRIV group when compared to the verum groups.
Only one subject was measured with a body temperature
$38.0uC (38.0uC one day after the 3rd vaccination in the PEV301
50 mg group). Most of the AEs (related or unrelated), either
observed by the physician in charge, or mentioned in the diary
card were of mild (39%) or moderate (59%) intensity. Only 2%
experienced severe AEs. Several laboratory values were reported
to be outside the normal ranges during the trial. However, none of
them was judged as clinically significant by the investigator. After
pooling groups and doses, the parameters most often outside the
normal ranges were: red blood cells count (45 values), ALAT (29
values), CRP (19 values), white blood cells count (15 values) and
haemoglobin (14 values).
Immunogenicity ELISA was performed with blood samples
taken during the screening visit, at the days of the 2nd and 3rd
vaccination 21 days after each vaccination and one year after the
third vaccination. Mean ELISA endpoint titers are given in
Table 3 and the antibody titers of the optimal doses are shown in
figure 2.
Indices of responses of the two PEV301 50 mg groups were
significantly higher than those of the 10 mg group at all time points
(p = 0.00003 between screening visit and week 4, p = 0.00003 at
week 9/10, p = 0.001 at week 26/27 and p = 0.00003 at week 29/
30), demonstrating that the dose of 50 mg AMA49-C1 was
superior to that of 10 mg. While all volunteers in the 50 mg groups
reached a titer .1:500 after the second and third immunization,
IRIV Peptide Malaria Vaccine
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none of the PEV301 10 mg group reached this titer (Table 3).
Nevertheless, there was a significant difference between the
response indices (shown in figure 3a) of PEV301 10 mg after the
second and third immunization versus that of the IRIV (control
group) (both p = 0.004). Differences in response indices between
groups PEV301 50 mg and PEV301 & 302 50 mg were not
statistically significant at weeks 4, 9/10, 12/14, 26/27 and 29/30
(p = 0.37, 0.37, 0.06, 0.07 and 0.1 respectively), indicating that the
combination with PEV302 did not interfere with the response to
PEV301. When comparing response indices after the first to the
ones after the second immunization in the PEV301 50 mg groups,
the difference was borderline significant (p = 0.09) indicating that
Table 1. Demographic characteristics at baseline.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PEV301 PEV302 PEV301+302 IRIV
10 mg 50 mg 10 mg 50 mg 50 mg of each
N= 8 N=8 N=8 N=8 N=8 N=6
Age (years)
Mean 26 27 28 28 25 26
Min-Max 22–37 22.–40 21–42 20–40 20–30 20–42
Weight (kg)
Mean 68.1 68.7 71.3 69.4 71.8 70.1
Min-Max 50.9–82.5 60.8–84.0 56.5–106.3 49.7–96.4 55.0–86.5 57.0–80.6
BMI
Mean 22.6 22.9 23 22 23.8 23.7
Min-Max 19.6–25.5 20.4–28.7 19.3–29.8 19.2–26.2 20.4–29.8 20.0–27.4
doi:10.1371/journal.pone.0001018.t001..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
Randomisation
PEV301
10 µg
n= 8
PEV301
50 µg
n= 8
 PEV302
10 µg
n= 8
Allocation
PEV302
50 µg
n= 8
PEV301 + 302
50 µg
n= 8
Enrollment
IRIV
n= 6
n=8 n=8n=8 1st vaccination n=8 n=8 n=6
n=6
n=7
1 discontinued due to
tonsillitis
n=82nd vaccination
n=7
1 discontinued due to
tooth abscess
n=8n=8
n=8 n=8 n=7 3rd vaccination
n=7
1 discontinued due to
persistant
dyshidrosis
n=7 n=6
Safety analysisn=8n=8n=8 n=8 n=8 n=6
Immunogenicity
analysis
Per Protocol*
n=8 n=7 n=5 n=7 n=6 N=4
Figure 1. Study flowchart
doi:10.1371/journal.pone.0001018.g001
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Table 2. Vaccine-related systemic adverse events
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vaccine PEV301 PEV302 PEV301 & 302 IRIV
10 mg 50 mg 10 mg 50 mg 50 mg each
Stdy group n= 8 n= 8 n= 8 n =8 n =8 n =6
After 1st immunization
Headache – 1 12.5% 2 25.0% – – –
Nasopharyngitis 1 12.5% – – – – –
Rhinitis 1 12.5% – – – –
Dyshidrosis – – – 1 12.5% – –
Number of participants with at least one AE 1/8 12.5% 2/8 25.0% 2/8 25.0% 1/8 12.5% 0/8 0% 0/6 0%
After 2nd immunization
Headache – 1 12.5% – 1 12.5% – –
Pharyngolarnyngeal pain – 2 25.0% – – – –
Ear pain – 1 12.5% – – – –
Rhinitis – 1 12.5% – – – –
Nausea – – – 1 12.5% – –
Vertigo – – – 1 12.5% – –
Fatigue – – – 1 12.5% – –
Malaise – – – 1 12.5% – –
Number of participants with at least one AE 0/8 0% 2/8 25.0% 0/7 0% 2/8 25.0% 0/7 0% 0/6 0%
After 3rd immunization
Pyrexia – 1 14.3% – – – –
Rhinitis – – 1 14.3% – – –
Asthenia – – – 1 14.3% – –
Vertigo – – – 1 14.3% – –
Vaginal infection – – – – 1 14.3% –
Headache – – 1 14.3% – – –
Number of participants with at least one AE 0/8 0.0% 1/8 12.5% 2/7 28.6% 1/7 14.3% 1/7 14.3% 0/6 0.0%
Notes: These are all solicited and unsolicited AEs reported in the CRF and in the diary cards, and judged by the clinician in charge to be possibly related to the vaccine.
The AEs in italics are those that occurred in the 4 days following vaccination (solicited). The values in bold indicate the number of AEs experienced.
doi:10.1371/journal.pone.0001018.t002..
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Table 3. Geometric means of anti-AMA49-C1 and anti-UK-39 IgG endpoint titers in ELISA and number of volunteers that
seroconverted
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vaccine PEV301 PEV302 PEV301 & PEV302 IRIV
Dose 10 mg 50 mg 10 mg 50 mg 50 mg
Study group Group A Group C Group B Group D Group E Group F*
Target antigen in ELISA AMA49-C1 AMA49-C1 UK-39 UK-39 AMA49-C1 UK-39 AMA49-C1 UK-39
Titers after 1st injection 77 6893 425 488 5593 392 25 77
95% CI 21-289 2057-28893 40-4559 10-23019 1654-18911 24-6391 25-25
Titers after 2nd injection 360 45614 5658 1449 18813 11404 25 77
95% CI 88-1479 20170-103156 1064-30083 61-34615 6849-51676 963-135025 25-25
Titers after 3rd injection 582 29117 19993 4307 16600 21945 25 77
95% CI 248-1367 11850-71541 2734-146208 243-76258 6391-43112 2892-166548 25-25
Titers 1 year after 3rd n.d. 3342 3200 n.d. 1213 696 n.d. n.d.
Nb. responders after 1st 2/8 6/8 4/7 3/7 7/7 3/7 0/6 1/6
Nb. responders after 2nd 5/8 8/8 7/7 5/7 7/7 6/7 0/6 1/6
Nb. responders after 3rd 5/8 8/8 7/7 6/7 7/7 7/7 0/6 1/6
Nb. responders 1 year after 3rd n.d. 7/8 5/6 n.d. 5/5 3/5 n.d. n.d.
*Controls included simultaneously to Group A and 3 (301) or 2 and 4 (302)
n.d.: not done
doi:10.1371/journal.pone.0001018.t003.
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the initial response was possibly boosted by the second administra-
tion. There was no additional benefit of having a third immunization
(p = 0.7). All volunteers in the two 50 mg groups had developed an
IgG response after the second immunization, whereas 62.5% (5/8) of
the volunteers in the 10 mg group seroconverted. Importantly,
antibody titers evaluated one year after the third immunization had
remained high (Fig. 2 and Tab. 3).
With PEV302 the highest mean ELISA titers were observed
after three injections, versus two for both PEV301 50 mg groups
(Table 3 and figure 2). In contrast to the results with PEV301,
mean ELISA endpoint titers of the group receiving 10 mg of the
antigen were higher than those receiving 50 mg. Furthermore, all
volunteers in the PEV302 10 mg group, but only 11/14 in the two
PEV302 50 mg groups had seroconverted after two injections.
After the third immunization, all volunteers in the PEV302 10 mg
group, but only 11/14 in the two PEV302 50 mg groups reached
an ELISA titer .1:500. The percentage of volunteers reaching
this titer increased with each immunization (Table 3). Response
indices of the three groups receiving PEV302 were not
significantly different (see figure 3b) [comparing group B versus
E (combination) p = 0.79 between screening visit and week 4,
p = 0.84 at week 9/10, p = 0.95 at week 12/14, p = 0.79 at week
26/27 and p = 0.88 at week 29/30, and comparing group D versus
E (combination) p = 0.92 between screening visit and week 4,
p = 0.60 at week 9/10, p = 0.34 at week 12/14, p = 0.42 at week
26/27 and p = 0.28 at week 29/30), demonstrating that the
combination of PEV302 with PEV301 did not interfere with the
response to PEV302. However, the index of response obtained in
the PEV301 & 302 50 mg group was higher than that of PEV302
50 mg group at all time points (although not statistically
significant), suggesting that the combination with PEV301 may
improve the response to PEV302. When comparing response
indices after the first to the ones after the second immunization in
the 10 mg group, the difference was borderline significant
(p = 0.056) indicating that the initial response was boosted by the
second administration. There was no significant additional benefit
of having a third immunization (p = 0.22). As for PEV301,
antibody titers tested one year after the last immunization had
remained high (Fig. 2 and Tab. 3).
In contrast to PEV301 and PEV302, no significant ELISA
endpoint titers and response indices were observed against the
malaria antigens in the control participants receiving IRIVs only.
The results after ITT analysis are perfectly superposable to those
obtained after PP analysis (data not shown).
DISCUSSION
Interpretation
This is the first clinical trial that tested two new technology
platforms in malaria vaccinology: synthetic peptides were
optimized for eliciting parasite binding and inhibitory antibodies
in iterative cycles of compound design, synthesis and immunolog-
ical profiling and IRIV were tested as an immunopotentiating
delivery system for PE-peptide conjugates. The results presented in
this paper prove the relevance and the feasibility of the concept: i)
GMP formulated material can be easily and quickly manufac-
tured, ii) the vaccine formulation is safe, and iii) the vaccine
formulation is immunogenic leading to seroconversion of all
volunteers after two injections with an appropriate antigen dose.
In terms of safety, the antigen delivery platform (IRIVs) used for
the tested vaccines is already commercialized and has been given
to ,20 million people, including children and infants.[15] This
safety record is a major advance, since, the two malaria vaccines
that have shown some efficacy in Phase IIb trials in endemic areas
are formulated in adjuvants that have been given at best to only
a few thousands of subjects so far.[16–17] Also, although probably
safe, these new adjuvants are quite reactogenic.[18–19] As with
other vaccine types, rare serious adverse events have been reported
following immunizations with synthetic malaria peptides[20], but
these may have occurred, because the doses of antigen were too
high for the potent adjuvant used. Since the two synthetic antigens
used in the present study were applied in lower doses and
combined with the human approved IRIVs we expected an
excellent safety profile. This was confirmed by our results that
showed that the virosome-formulated PE-peptide conjugates
AMA49-C1 and UK-39 as well as the combination of both are
safe. The local reactogenicity was minimal with only mild or
moderate pain, and no redness or swelling. This contrasts with
results obtained in Phase I trials with recombinant malaria
proteins formulated with ASO2A or Montanide ISA 720, or DNA
vaccines in viral vectors.[19] There was no difference in the
incidence rate and intensity of AEs between the participants given
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Figure 2. Geometric mean anti-AMA49-C1 and anti-UK-39 IgG endpoint titers in ELISA of groups immunized with optimal doses of PEV301
(50 mg) or PEV302 (10 mg), or with 50 mg each of both antigens. Sera analyzed were collected during the screening visit, at the days of the 2nd and
3rd vaccination, 21 days after each vaccination and one year after the third vaccination
doi:10.1371/journal.pone.0001018.g002
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one or the other synthetic antigen, or both, and between the two
doses, which proves the safety of the formulation.
In terms of immunogenicity, the ELISA results demonstrate that
the formulation of synthetic peptides with virosomes elicited
a response in all volunteers immunized with an appropriate dose.
These results represent a proof of principle, i.e. they demonstrate
that virosomes are a suitable antigen delivery system for malaria
peptide antigens in humans and that immunogenetic restriction of
the response does not represent a serious limitation for this approach.
In the majority of volunteers immunized with PEV302, we observed
cross-reactivity with the target proteins on the cell surface of P.
falciparum sporozoites (data not shown). Also in the case of a minority
of PEV301 immunized volunteers development of an AMA-1
specific staining pattern of malaria blood stage parasites was found in
spite of variable background staining. These results demonstrate that
the two synthetic antigens display the native structure of antigenic
domains of the target antigens AMA-1 and CSP.
In the case of PEV301, the higher antigen dose (50 mg) was
significantly superior to the lower dose (10 mg) with respect to
mean antibody titers and seroconversion rate. For PEV302, the
trend was reverse. These results may imply that additional
antigens included in a multivalent vaccine will need a proper
dose-finding assessment. In the case of PEV301 and PEV302
trends observed in animal immunogenicity studies and the clinical
trial were comparable (Mueller et al., unpublished). Since the
combined delivery of PEV301 and PEV302 did not interfere with
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Figure 3. Geometric means of the ratios of geometric mean antibody endpoint titres (log scale) for samples taken three weeks after each
immunization with reference to pre-vaccination titers in sera taken at the screening visit (week-1). a) anti-AMA49-C1 IgG titers (Group A=PEV301
10 mg; Group C= PEV301 50 mg; Group E= PEV301&302 50 mg, Group F= IRIV) b) anti-UK-39 IgG titers (Group B=PEV302 10 mg; Group D=PEV302
50 mg; Group E= PEV301&302 50 mg, Group F= IRIV)
doi:10.1371/journal.pone.0001018.g003
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the development of an immune response to either of the two
components, it is hoped that the inclusion of additional antigens
should not be detrimental to the overall immunogenicity. In
addition, a persistent antibody titer was measured after one year.
Generalizability
This trial was performed in malaria-naı¨ve Caucasian adult
participants. The safety profile of this vaccine formulation is likely
to be quite similar when administered to children living in malaria
endemic areas. Indeed, it has been regularly observed that the
incidence of adverse events is lower in populations with pre-existing
immunity rather than higher. Moreover, IRIV have already been
successfully used as immunomodulators with antigens other than
malaria in developing countries. In terms of immunogenicity, the
100% seroconversion rate achieved in malaria naı¨ve volunteers
already after only two injections with the appropriate dose of antigen
is highly promising. Indeed, it is expected that the vaccine will boost
pre-existing immunity and the net result should be higher immune
responses in populations with natural exposure. The observation of
very high antibody titers after vaccination in one volunteer that had
some degree of preexisting malaria immunity at the start (and
therefore wrongly included) is quite promising in this respect and
justifies the planning of a Phase Ib trial in Africa.
Overall evidence
Influenza virosomes represent an innovative human-compatible
antigen delivery system that has already proven its suitability for
vaccine design, such as for hepatitis A and influenza vaccines that
are commercialized in many countries in the world (also for
children). The present trial is the first to test the safety and
immunogenicity of virosomes as carrier/adjuvant system for
synthetic peptides of Plasmodium falciparum in humans. The
excellent safety profile is in line with that observed with other
virosome-formulated commercialized vaccines, and should argue
for an excellent acceptability by the parents. The magnitude of the
antibody responses obtained in the present trial confirm previous
data from animal studies with virosome-formulated malarial
antigens [21], and from human studies with antigens other than
malaria. The observation that antibody responses were sustained
one year after vaccination, and their avidity increased over the
course of immunization (unpublished results) demonstrates the
appropriateness of this technology platform. These findings justify
thus the ongoing efforts to develop a virosome-formulated multi-
valent multi-stage malaria vaccine. Our approach of developing
optimized IRIV-formulated synthetic peptide vaccines should be
generally applicable and amenable for other infectious and non-
infectious diseases.
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